Oligodendrocytes (OLs) are the myelinating glia of the central nervous system. Injury to OLs causes myelin loss. In demyelinating diseases, such as multiple sclerosis, the remyelination is hindered principally due to a failure of the oligodendrocyte precursor cells (OPCs) to differentiate into mature OLs. To identify inducers of OPC to OL differentiation, a high-throughput screening based on myelin basic protein expression using neural progenitor cells-derived OPCs has been performed and, PD0325901-an MEK (MAPK kinase) inhibitor-is found to significantly enhance OPC to OL differentiation in a dose-and time-dependent manner. Other MEK inhibitors also display similar 
| INTRODUCTION
Myelin is a unique structure of the nervous system and is often considered as the electrical insulator on nerve fibers. As a matter of fact, myelin sheath not only enables rapid impulse conduction but also plays fundamental roles in modulating information flow within neural circuits and providing metabolic support for axons (Funfschilling et al., 2012; Lappe-Siefke et al., 2003; Morrison, Lee, & Rothstein, 2013; Nave & Werner, 2014; Saab, Tzvetanova, & Nave, 2013) . In the central nervous system (CNS), the myelinating cells are known as oligodendrocytes (OLs), a specialized type of glial cells originating from the neural stem cells (Bergles & Richardson, 2015; Takebayashi & Ikenaka, 2015) .
Developmentally, oligodendrocyte precursor cells (OPCs) give rise to immature (or premyelinating) and then mature (or myelinating) OLs that wrap neuronal axons and form myelin sheath (Emery, 2010; van Tilborg et al., 2018) . OPCs specifically express platelet-derived growth factor receptor (α-subunit, PDGFRα) and chondroitin sulfate proteoglycan neuron-glia antigen 2 (NG2) (Bergles & Richardson, 2015; Goldman & Kuypers, 2015) , which are downregulated when OPCs go into differentiation. During the differentiation process, O4, O1, 2 0 ,3 0 -cyclic nucleotide-3 0 -phosphohydrolase (CNPase), myelin basic protein (MBP), proteolipid protein (PLP), and myelin oligodendrocyte glycoprotein (MOG) are gradually expressed in an orderly manner (Barateiro & Fernandes, 2014; Craig et al., 2003; Scolding et al., 1989; Zhang, 2001 ).
Injury to OLs causes myelin loss, also termed demyelination. After acute demyelination, OPCs, as widely distributed and abundant in adult CNS, migrate to the lesion and differentiate into mature OLs which remyelinate the axons (Franklin, 2002; Franklin & Ffrench-Constant, 2008; Gensert & Goldman, 1997) . In demyelinating diseases such as multiple sclerosis, remyelination by adult OPCs is hindered principally due to a failure of OPCs to differentiate into mature OLs (Chang, Nishiyama, Peterson, Prineas, & Trapp, 2000; Keirstead, Levine, & Blakemore, 1998; Woodruff, Fruttiger, Richardson, & Franklin, 2004) . Therefore, identification of pathways and small molecules that promote OPC differentiation, remyelination, and functional recovery has received much attention.
Through image-based screen, benztropine has been identified to enhance remyelination by direct antagonism of M1 and/or M3 muscarinic receptors (Deshmukh et al., 2013) . Mei et al. (2016) carried out a screen focusing on GPCR modulators and identified 12 kappa-opioid receptor (KOR) agonists that enhance OPC to OL differentiation. Their study is consistent with Du et al.'s finding that U50488 targeting KOR ameliorates symptoms of EAE by promoting remyelination rather than immune suppression (Du et al., 2016) . Another screen of NIH Clinical Collection I and II libraries has also identified two drugs-miconazole and clobetasol-which are effective in promoting OL generation in vitro and remyelination in vivo (Najm et al., 2015) . We also developed a highthroughput screening assay based on the induction of MBP during OPC to OL differentiation, and vitamin C has been found to greatly promote OL differentiation, maturation, and remyelination (Guo, Suo, Cui, Yuan, & Xie, 2018 ).
Here we report the discovery that small molecule inhibitors of MAPK/ERK pathway, represented by PD0325901, significantly promote OPC to OL differentiation and myelin formation. In immune-and drug-mediated demyelination animal models, PD0325901 also shows significant therapeutic effects.
| MATERIALS AND METHODS

| Reagents
Laminin, poly-ornithine, thyroid hormone (T3), paraformaldehyde (PFA), bis(cyclohexanone)oxaldihydrazone (Cuprizone), Hoechst 33342, poly-D-lysine, papain, L-cysteine, insulin, transferrin, progesterone, putrescine, BSA, and 5-fluoro-2 0 -deoxyuridine were purchased from Sigma-Aldrich.
Collagenase A was purchased from Roche. EGF, bFGF, and PDGF-AA were purchased from Peprotech. PD0325901, CI-1040, AZD8330, and AZD6244 were purchased from MedChemExpress, and U0126 was purchased from Tocris.
| OPC differentiation
Neural progenitor cells (NPCs) were purified from the dissected cerebral cortex of E14.5 mouse embryos by suspension culture (Chen et al., 2007) . NPCs were expanded as neurospheres in the NPC medium (DMEM/F12 (Gibco) supplemented with 20 ng/ml EGF, 20 ng/ml bFGF, 2% B27 (Invitrogen), 100 units/ml penicillin, and 100 μg/ml streptomycin). Neurospheres were passaged every 2 days and never allowed to reach confluence. Neurospheres from Passages 3-5 were used for the differentiation assay. To generate OPCs, neurospheres were dissociated into single cells with accutase (Millipore, SF006) and seeded onto poly-ornithine (5 μg/ml) plus laminin (1 μg/ml)-coated plates in OPC medium (DMEM/F12 supplemented with 10 ng/ml bFGF, 10 ng/ml PDGF-AA, 2% B27, 100 units/ml penicillin, and 100 μg/ml streptomycin). Two days later, PDGF-AA and bFGF were withdrawn to induce OPC differentiation (OL medium), and cells were stimulated with compounds or DMSO control for another 4-5 days.
| High-throughput screening and imaging
For the primary screen, neurospheres were dissociated into single cells and seeded at a density of 8,000 cells per well onto poly-ornithine (5 μg/ml) plus laminin (1 μg/ml)-coated 96-well plates in OPC medium for 2 days. Then OPCs were induced to differentiation into OLs as previously described. And various compounds at a concentration of 20 μM were added at the same time. Thyroid hormone T3 (100 nM) and DMSO (0.2%, v/v) 
| Immunofluorescence staining
Cells were fixed with 4% PFA in phosphate-buffered saline (PBS) for 15 min at room temperature and blocked in PBS containing 1% BSA and 0.3% Triton for 30 min at room temperature. Then cells were incubated with the relevant primary antibody at 4 C overnight and the appropriate fluorescence-conjugated secondary antibody for 1 hr at room temperature. Nuclei were stained with Hoechst 33,342
(10 mg/ml). Antibodies used in this assay were as follows: anti-MBP (Covance, SMI-94R, 1:500), anti-NF-200 (Sigma, N4142, 1:1000), anti-O4 (R&D Systems, MAB1326, 1:1200), and anti-CNPase (Millipore, MAB326, 1:1200).
| OPC-DRG neuron co-culture
Dorsal root ganglions (DRGs) isolated from P5-P10 C57BL/6 pups were incubated in Hank's balanced salt solution (HBSS) containing papain (3 U/ml) and L-cysteine (0.36 mg/ml) for 10 min at 37 C. After removal of papain solution, DRGs were further incubated in HBSS containing collagenase A (100 U/ml) for 10 min at 37 C. After thorough washing, the dissociated DRG neurons were seeded at a density of 20,000 cells/well onto poly-D-lysine (80 μg/ml) and rat tail collagen (25 μg/ml) coated 48-well plate and maintained in myelination medium (DMEM (Gibco), 2% B27, 1% Glutamax (Gibco), insulin (5 μg/ml), transferrin (50 μg/ml), 0.5% FBS, progesterone (0.2 μM), putrescine (100 μM), BSA (0.1 mg/ml), sodium selenite (5 ng/ml), 100 units/ml penicillin, and 100 μg/ml streptomycin) for 9 days, and 5-fluoro-2 0 -deoxyuridine (10 μM) was added to remove contaminating glia cells for the first 7 days. After 9 days, 3 × 10 4 OPCs freshly isolated from P0-P2 C57BL/6 pups cortices with anti-AN2 microbeads (Miltenyi) were added per well to DRG neurons, and the co-cultures were maintained for another 6 days in myelination medium. 
| Histology and immunohistochemical analysis
Paraffin-embedded coronal sections of brains were stained with Luxol fast blue (LFB, Sigma, S3382) to assess remyelination. Images were taken and quantitative image analysis was performed using Image-Pro Plus. Region of corpus callosum was initially marked using the "irregular AOI" tool, blue areas were then counted within the lesion using the and quantitative image analysis was performed using Image-Pro Plus.
| Electron microscopy
Spinal cords and brains were isolated from 4% PFA perfused mice, and fixed in 4% PFA overnight. Demyelinated white matter of the spinal cords and corpus callosum of the brains were isolated and fixed in PBS 
| Western blot
OLs differentiated from NPC-derived OPCs were lysed and boiled at 95-100 C for 10 min in sample buffer (50 mM Tris-HCl, 2% w/v SDS, 10% glycerol, 1% β-mercaptoethanol, 0.01% bromophenyl blue PD0325901 promotes the OPC to OL fate determination, and once more immature OLs are generated, more mature OLs will be obtained. observed in the white matter region (Figure 5d,g ). In PD0325901-treated mice, demyelination was significantly mitigated with increased number of GST-pi + mature OLs, and reduced number of NG2 + OPCs (Figure 5b-g ).
Furthermore, g-ratios (axonal diameter to total myelinated fiber diameter) of remyelinated spinal cord axons were analyzed by transmission electron microscopy. Demyelination was evidenced by increased g-ratio in EAE mice compared to naive ones (Figure 5h Other studies have demonstrated that blockade of ERK promotes Th17 differentiation (Cui et al., 2009; Tan & Lam, 2010) without affecting the Th1 subset (Cui et al., 2009) . And inhibition of ERK does not significantly affect Th17 production has also been reported (Lu et al., 2010 ). The conclusion from previous studies has been controversial.
To further confirm the ability of PD0325901 in enhancing remyelination in vivo, we conducted the T-cell-independent cuprizoneinduced demyelination model (Doan et al., 2013; Matsushima & Morell, 2001 ).
| PD0325901 promotes myelin recovery in druginduced demyelination model
Mice were fed with a diet containing 0.2% (w/w) cuprizone for 5 weeks to induce complete demyelination (Figure 6a-c) . Upon cuprizone withdrawal, vehicle or PD0325901 (10 mg/kg) was administrated by daily i.p. injection for 1 or 2 weeks (Figure 6a ). Mice were euthanized and myelination at the corpus callosum was evaluated by Luxol fast blue The myelin status was further evaluated by transmission electron microscopy. After 5 weeks of cuprizone treatment, very few axons in corpus callosum remained myelinated (Figure 6g-i) . Two weeks after cuprizone withdrawn, spontaneous remyelination could (Bansal & Pfeiffer, 1997; Canoll, Kraemer, Teng, Marchionni, & Salzer, 1999; Fressinaud, Vallat, & Labourdette, 1995) . Other studies have reported that pharmacological inhibition of ERK1/2 signaling negatively regulates transition of early progenitors to the late progenitor stage, but does not affect the maturation of OLs (Baron, Metz, Bansal, Hoekstra, & de Vries, 2000; Guardiola-Diaz, Ishii, & Bansal, 2012) .
One study has claimed that ERK1/2 signaling promotes OL myelination in vitro (Xiao et al., 2012 (Ishii, Furusho, & Bansal, 2013; Ishii, Fyffe-Maricich, Furusho, Miller, & Bansal, 2012; Newbern et al., 2011) . Conditional deletion of ERK2 in CNP + cells on an ERK1 null background leads to reduction of myelin sheath thickness without affecting OPC proliferation and differentiation, as mutants fail to upregulate the major myelin genes during active myelination . Likewise, sustained activation of ERK1/2 via the expression of constitutive active MEK1 using the CNP-Cre driver significantly increases myelin sheath thickness during development, which is independent of OPC to OL differentiation or initiation of myelination (Ishii et al., 2013) . In the same study, increased activity of ERK1/2 in Olig1 but does not directly reduce their capacity to differentiate into OLs (Ishii et al., 2013) .
Interestingly, deletion of ERK2 in Olig2 + cells on an ERK1 null background leads to reduced proliferation of PDGFRα + OPCs, and a more ramified, complex morphology of S100β + OLs, suggesting that loss of ERK1/2 triggers premature differentiation which is also evidenced by a clear increase in MBP labeling in vivo (Newbern et al., 2011) . The early lethality of Erk1/2 CKO(Olig2) mice limited the analysis to only the initial stages of myelination. But these results imply a negative role of ERK1/2 signaling on OL differentiation and myelination, conflicted with previous studies mentioned above and supported our findings.
Most of these genetic manipulations are not time-dependent, which may complicate things further. There is a study that evaluated the role of ERK1/2 signaling in remyelination using the mice expressing constitutively active MEK1 under the control of CNP-Cre driver (Fyffe-Maricich, Schott, Karl, Krasno, & Miller, 2013) . In mutant mice, thicker myelin sheath in remyelinated axons was observed. But a question was also raised that the demylination extent may differ in WT and mutant mice as upregulated ERK1/2 signaling in mutant mice sustains a whole lifetime. Our study specifically modulated ERK1/2 signaling in 
